SkyePharma to Conduct Study with Respivert

Share On Facebook
share on Linkedin

SkyePharma (LSE:SKP), a pharmaceutical company specialising in the development of inhaled products and drug delivery technologies, announced today that it has signed a second agreement to conduct a feasibility study with RespiVert, a small molecule drug discovery company specializing in respiratory disorders.   This agreement comes on the heels of the successful completion of a similar programme over the past fifteen months for another Respivert compound.

This feasibility study will seek to develop a new dry powder inhaler for patients afflicted with severe respiratory ailments, such as chronic obstructive pulmonary disease, and severe asthma.  Shares of SkyePharma were up 13% to 37.75p as of 10:46 GMT.

Executive Comments

SkyePharma CEO Peter Grant:

“We are pleased that the excellent progress with the first feasibility project has led to this follow-on project, and we look forward to collaborating further with RespiVert to develop important new products for patients suffering from respiratory diseases. Over the past 20 years, SkyePharma has established world-class respiratory development expertise covering both metered dose and dry powder inhalation products.”

Company Spotlight

SkyePharma is a developer of inhaled products and drug delivery technologies whose products are marketed throughout the world by leading pharmaceutical companies.  The company has eleven approved products in the areas of oral and topical delivery and licence and revenue-generating products in inhalation and injectable technologies.

 About SkyePharma
 About Respivert
↑ SkyePharma Respivert Contract

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Leave A Reply

Do you want to write for our Newspaper? Get in touch:

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220818 17:06:29